Patents by Inventor Satoko Hamamura
Satoko Hamamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11051496Abstract: The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.Type: GrantFiled: March 23, 2018Date of Patent: July 6, 2021Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, CHUGAI SEIYAKU KABUSHIKI KAISHA, PHOENIXBIO CO., LTD.Inventors: Michinori Kohara, Koichi Jishage, Yosuke Kawase, Chise Mukaidani, Hiroki Oshita, Satoko Hamamura
-
Publication number: 20190335724Abstract: The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.Type: ApplicationFiled: March 23, 2018Publication date: November 7, 2019Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, CHUGAI SEIYAKU KABUSHIKI KAISHA, PHOENIXBIO CO., LTD.Inventors: Michinori KOHARA, Koichi JISHAGE, Yosuke KAWASE, Chise MUKAIDANI, Hiroki OSHITA, Satoko HAMAMURA
-
Patent number: 9955675Abstract: The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.Type: GrantFiled: April 25, 2013Date of Patent: May 1, 2018Assignees: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, CHUGAI SEIYAKU KABUSHIKI KAISHA, PHOENIXBIO CO., LTD.Inventors: Michinori Kohara, Koichi Jishage, Yosuke Kawase, Chise Mukaidani, Hiroki Oshita, Satoko Hamamura
-
Patent number: 9420769Abstract: A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes, is provided. The method comprises transplanting human hepatocytes into a non-human animal characterized by (i) being immunodeficient, (ii) having liver damage, and (iii) lacking the functions of an endogenous Cyp3a gene.Type: GrantFiled: October 12, 2012Date of Patent: August 23, 2016Assignees: PHOENIXBIO CO., LTD., NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITYInventors: Mitsuo Oshimura, Yasuhiro Kazuki, Chise Mukaidani, Takashi Shimada, Masakazu Kakuni, Satoko Hamamura, Hidetaka Kamimura, Akio Kawamura, Naoyuki Nakada, Masato Ohbuchi, Kota Kato
-
Publication number: 20150128298Abstract: The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.Type: ApplicationFiled: April 25, 2013Publication date: May 7, 2015Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, PHOENIXBIO CO., LTD., CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Michinori Kohara, Koichi Jishage, Yosuke Kawase, Chise Mukaidani, Hiroki Oshita, Satoko Hamamura
-
Publication number: 20140241991Abstract: A chimeric non-human animal having an in vivo human hepatocyte population, wherein the effects of non-human animal cells on drug metabolism are suppressed or deleted is provided. A method for producing a chimeric non-human animal that lacks a drug-metabolizing system or has a suppressed drug-metabolizing system and is provided with a drug-metabolizing system driven by human hepatocytes, is provided. The method comprises transplanting human hepatocytes into a non-human animal characterized by (i) being immunodeficient, (ii) having liver damage, and (iii) lacking the functions of an endogenous Cyp3a gene.Type: ApplicationFiled: October 12, 2012Publication date: August 28, 2014Applicants: PHOENIXBIO CO., LTD., NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITYInventors: Mitsuo Oshimura, Yasuhiro Kazuki, Chise Mukaidani, Takashi Shimada, Masakazu Kakuni, Satoko Hamamura, Hidetaka Kamimura, Akio Kawamura, Naoyuki Nakada, Masato Ohbuchi, Kota Kato